CY1106355T1 - Πρωτεϊνη συνδεομενη με αποπτινη - Google Patents

Πρωτεϊνη συνδεομενη με αποπτινη

Info

Publication number
CY1106355T1
CY1106355T1 CY20071100310T CY071100310T CY1106355T1 CY 1106355 T1 CY1106355 T1 CY 1106355T1 CY 20071100310 T CY20071100310 T CY 20071100310T CY 071100310 T CY071100310 T CY 071100310T CY 1106355 T1 CY1106355 T1 CY 1106355T1
Authority
CY
Cyprus
Prior art keywords
apoptin
associated protein
new therapeutic
apoptosis
sequentially
Prior art date
Application number
CY20071100310T
Other languages
English (en)
Inventor
Mathieu Hubertus Maria Noteborn
Astrid Adriana Anna Maria Danen-Van Oorschot
Original Assignee
Leadd B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP99202858A external-priority patent/EP1081226A1/en
Priority claimed from EP99203465A external-priority patent/EP1108785A1/en
Application filed by Leadd B.V. filed Critical Leadd B.V.
Publication of CY1106355T1 publication Critical patent/CY1106355T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Η εφεύρεση σχετίζεται με το πεδίο της απόπτωσης. Η εφεύρεση παρέχει νέες θεραπευτικές δυνατότητες, για παράδειγμα νέες συνδυαστικές θεραπείες ή νέες θεραπευτικές ενώσεις που μπορούν να δουλέψουν μόνες τους, διαδοχικά, ή μαζί με αποπτίνη, ειδικά σε αυτές τις περιπτώσεις που το p53 είναι (μερικώς) μη λειτουργικό.
CY20071100310T 1999-09-02 2007-03-06 Πρωτεϊνη συνδεομενη με αποπτινη CY1106355T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99202858A EP1081226A1 (en) 1999-09-02 1999-09-02 Apoptin-associating protein
EP99203465A EP1108785A1 (en) 1999-10-21 1999-10-21 Apoptin-associating protein
EP00203042A EP1083224B1 (en) 1999-09-02 2000-09-01 Apoptin-associating protein

Publications (1)

Publication Number Publication Date
CY1106355T1 true CY1106355T1 (el) 2011-10-12

Family

ID=26153361

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100310T CY1106355T1 (el) 1999-09-02 2007-03-06 Πρωτεϊνη συνδεομενη με αποπτινη

Country Status (20)

Country Link
US (2) US7317096B1 (el)
EP (1) EP1083224B1 (el)
JP (1) JP2003510030A (el)
CN (1) CN100513565C (el)
AT (1) ATE347597T1 (el)
AU (1) AU781127B2 (el)
BR (1) BR0013743A (el)
CA (1) CA2383784A1 (el)
CY (1) CY1106355T1 (el)
DE (1) DE60032201T2 (el)
DK (1) DK1083224T3 (el)
EA (1) EA005933B1 (el)
ES (1) ES2277815T3 (el)
HU (1) HUP0202688A2 (el)
IL (2) IL148469A0 (el)
NO (1) NO20021067L (el)
NZ (1) NZ517740A (el)
PL (1) PL204275B1 (el)
PT (1) PT1083224E (el)
WO (1) WO2001016165A2 (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042461A2 (en) * 1999-12-10 2001-06-14 Leadd B.V. Apoptin-associating protein
KR20110008086A (ko) 2008-04-11 2011-01-25 메리맥 파마슈티컬즈, 인크. 인간 혈청 알부민 링커 및 그 콘쥬게이트
WO2011100428A2 (en) * 2010-02-10 2011-08-18 The Uab Research Foundation Compositions for improving bone mass

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9002008A (nl) * 1990-09-12 1992-04-01 Stichting Centr Diergeneeskund Recombinant dna en rna en daarvan afgeleide produkten.
EP0878546A1 (en) * 1997-04-15 1998-11-18 Leadd B.V. A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or apoptin
ES2249774T3 (es) 1994-12-22 2006-04-01 Novartis Ag Proteinas serina/tronina quinasas nucleares.
ES2200065T3 (es) * 1995-06-07 2004-03-01 Leadd B.V. Utilizacion de apoptina.
CA2283299A1 (en) 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 186 human secreted proteins
SK286235B6 (sk) * 1997-08-12 2008-06-06 Leadd B. V. Spôsob zisťovania transformačnej schopnosti látky, spôsob zisťovania predispozície buniek stať sa nádorovými bunkami, použitie nukleovej kyseliny a diagnostická súprava
EP0924296A3 (en) * 1997-12-03 2001-08-01 Leadd B.V. Methods and means for inducing apoptosis by interference in RNA processing
EP0921192A1 (en) * 1997-12-03 1999-06-09 Leadd B.V. Molecules interacting with apoptin
EP0927757A1 (en) * 1997-12-03 1999-07-07 Leadd B.V. Methods and means for inducing apoptosis by interfering with Bip-like proteins
US20030105315A1 (en) 1998-04-09 2003-06-05 Metagen Pharmaceuticals Gmbh Human nucleic acid sequences from ovarian tumor tissue
AU3885999A (en) * 1998-05-05 1999-11-23 Incyte Pharmaceuticals, Inc. Human transcriptional regulator molecules
EP1106691A1 (en) 1999-12-10 2001-06-13 Leadd B.V. Apoptin-associating protein
EP1111045A3 (en) 1999-12-10 2001-09-19 Leadd B.V. Apoptin-associating protein
WO2001042461A2 (en) 1999-12-10 2001-06-14 Leadd B.V. Apoptin-associating protein
US6809189B2 (en) 2000-01-17 2004-10-26 Leadd B.V. Apoptin-associating protein
EP1138765A1 (en) 2000-03-27 2001-10-04 Leadd B.V. Apoptin-associating proteins AAP-5 and AAP-6

Also Published As

Publication number Publication date
AU781127B2 (en) 2005-05-05
WO2001016165A3 (en) 2001-09-20
HUP0202688A2 (en) 2002-12-28
PT1083224E (pt) 2007-03-30
ATE347597T1 (de) 2006-12-15
JP2003510030A (ja) 2003-03-18
EP1083224A3 (en) 2001-04-25
EA005933B1 (ru) 2005-08-25
EP1083224B1 (en) 2006-12-06
BR0013743A (pt) 2005-01-11
DE60032201D1 (de) 2007-01-18
DK1083224T3 (da) 2007-04-10
CA2383784A1 (en) 2001-03-08
EA200200321A1 (ru) 2002-08-29
WO2001016165A2 (en) 2001-03-08
NO20021067D0 (no) 2002-03-04
PL204275B1 (pl) 2009-12-31
IL148469A0 (en) 2002-09-12
IL148469A (en) 2009-02-11
US20080176231A1 (en) 2008-07-24
CN100513565C (zh) 2009-07-15
DE60032201T2 (de) 2007-09-20
ES2277815T3 (es) 2007-08-01
PL354285A1 (en) 2003-12-29
NZ517740A (en) 2003-09-26
NO20021067L (no) 2002-05-02
US7317096B1 (en) 2008-01-08
CN1387569A (zh) 2002-12-25
EP1083224A2 (en) 2001-03-14
US7767790B2 (en) 2010-08-03
AU7324200A (en) 2001-03-26

Similar Documents

Publication Publication Date Title
CY1108722T1 (el) Πολυκυκλικες ενωσεις και η χρηση τους ως αναστολεων των ενζυμων parp, vegfr2 και mlk3
ATE361922T1 (de) Pyrrol-substituierte indole als inhibitoren von pai-1
TR200000782T2 (tr) Resorsinol türevleri.
UY25313A1 (es) Inhibidores del dominio sh2 de la familia src
CY1105758T1 (el) Τροποποιημενη απιμιναση αργινινης
CY1106532T1 (el) Ετερολογος εκφραση των πρωτεϊνων της neisseria
GT200600407A (es) Compuestos ppar activos
CY1105295T1 (el) Αντιμετωπιση αυτοανοσων νοσων με ανταγωνιστες που προσδενονται σε δεικτες επιφανειας κυτταρων β
EA200100688A1 (ru) АЗОТСОДЕРЖАЩИЕ ГЕТЕРОБИЦИКЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Xa
PT1214936E (pt) Utilizacao de derivados de tiazolidina ou pirrolidina de aminoacidos como agentes anti-hiperglicemicos
EA200001193A1 (ru) 2-фенил-1-[4-(2-аминоэтокси)бензил]индол в комбинации с эстрогенами
CY1106223T1 (el) Μεθοδοι διαμορφωσης λειτουργιας σepινης/θρεονινης πρωτεϊνης κινασης με βασισμενες σε 5-αζακινοξαλινη ενωσεις
BR9913745A (pt) Cetonas de piridina úteis como herbicidas
BRPI0410348A (pt) compostos e usos dos mesmos na modulação de amilóide-beta
CY1110104T1 (el) Παραγωγα της πιπεραζινης ως αναστολεις ταχυκινινων
EA200200105A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ PPARγ;
CY1109153T1 (el) Ενωσεις υποκατεστημενου κυκλοπεντανιου και κυκλοπεντενιου χρησιμες ως αναστολεις νευραμινιδασης
DE69919700D1 (de) Überbrückte indenopyrrolocarbazole
EA201270630A1 (ru) Гетероциклические сетр ингибиторы
DE602004031372D1 (de) Nachweis von staphylococcus
ES2151249T3 (es) Hidroxiamidino-derivados utiles como inhibidores de oxido nitrico sintasa.
DOP2001000219A (es) Applicator
ATE383172T1 (de) Oligonukleotide welche spezifisch retrovirale nukleokapsid-proteine binden
EA200000519A1 (ru) 2-АРИЛБЕНЗО[b]ТИОФЕНЫ, ПОЛЕЗНЫЕ ДЛЯ ЛЕЧЕНИЯ СИНДРОМА ЭСТРОГЕННОЙ НЕДОСТАТОЧНОСТИ
CY1106355T1 (el) Πρωτεϊνη συνδεομενη με αποπτινη